Aspirin and the risk of colorectal cancer in women.

BACKGROUND Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists. The effects of the dose and the duration of aspirin consumption on the risk of colorectal cancer are not well understood. METHODS We determined rates of colorectal cancer according to the number of consecutive years of regular aspirin use (defined as two or more tablets per week) among women in the Nurses' Health Study who reported regular aspirin use on three consecutive questionnaires (1980, 1982, and 1984) and compared the rates in this group with the rates among women who said they did not use aspirin. Cases of cancer occurring from 1984 through 1992 (the eight years after the 1984 questionnaire) were included. RESULTS From 1984 through 1992, we documented 331 new cases of colorectal cancer during 551,651 person-years of follow-up. Women who consistently took two or more aspirin tablets per week had no appreciable reduction in the risk of colorectal cancer as compared with nonusers after four years (relative risk, 1.06; 95 percent confidence interval, 0.78 to 1.45) or after five to nine years (relative risk, 0.84; 95 percent confidence interval, 0.55 to 1.28). There was a slight reduction in risk among women who took aspirin for 10 to 19 years, but it was not statistically significant (relative risk, 0.70; 95 percent confidence interval, 0.41 to 1.20). However, there was a statistically significant reduction after 20 years of consistent use of aspirin (relative risk, 0.56; 95 percent confidence interval, 0.36 to 0.90; P for trend = 0.008). The maximal reduction in risk was observed among women who took four to six tablets per week; higher doses had a similar apparent benefit. Controlling for risk factors for colorectal cancer, including diet, did not change the results, and the earlier diagnosis and removal of colorectal adenomas among aspirin users did not account for the results. CONCLUSIONS Regular aspirin use, at doses similar to those recommended for the prevention of cardiovascular disease, substantially reduces the risk of colorectal cancer. However, this benefit may not be evident until after at least a decade of regular aspirin consumption.

[1]  D. Appleton,et al.  A protective effect of sulindac against chemically‐induced primary colonic tumours in mice , 1988, The Journal of pathology.

[2]  W. Willett,et al.  Test of the National Death Index. , 1984, American journal of epidemiology.

[3]  S. Stryker,et al.  Natural history of untreated colonic polyps. , 1987, Gastroenterology.

[4]  J D Hardcastle,et al.  Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. , 1993, BMJ.

[5]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[6]  J. F. Fraumeni,et al.  Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.

[7]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[8]  J. Manson,et al.  Low-dose aspirin and incidence of colorectal tumors in a randomized trial. , 1993, Journal of the National Cancer Institute.

[9]  E. Rimm,et al.  Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.

[10]  T. Kudo,et al.  Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. , 1981, Cancer research.

[11]  T. Muto,et al.  The evolution of cancer of the colon and rectum , 1974, Cancer.

[12]  L. Marnett.  Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.

[13]  F. Macrae,et al.  Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. , 1982, Gastroenterology.

[14]  H. Adami,et al.  Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. , 1994, Gastroenterology.

[15]  M. Ghia,et al.  Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. , 1994, Cancer letters.

[16]  M. Thun,et al.  Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop , 1994, Cancer.

[17]  M. Thun,et al.  Aspirin use and risk of fatal cancer. , 1993, Cancer research.

[18]  N. Petrelli,et al.  Aspirin use, cancer, and polyps of the large bowel , 1993, Cancer.

[19]  D. Alberts,et al.  Inhibiting intracellular signalling as a strategy for cancer chemoprevention. , 1994, European journal of cancer.

[20]  J. Baron,et al.  Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. , 1993, Journal of the National Cancer Institute.

[21]  W. Willett,et al.  Dietary fat and the risk of breast cancer. , 1987, The New England journal of medicine.

[22]  M. Laakso,et al.  Cancer mortality in patients with rheumatoid arthritis. , 1986, The Journal of rheumatology.

[23]  B. Henderson,et al.  Aspirin use and chronic diseases: a cohort study of the elderly. , 1989, BMJ.

[24]  E. Rimm,et al.  Folate, methionine, and alcohol intake and risk of colorectal adenoma. , 1993, Journal of the National Cancer Institute.

[25]  M. Pollard,et al.  Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. , 1981, Science.

[26]  G. Kelloff,et al.  Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. , 1987, Cancer research.

[27]  W. Willett,et al.  A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. , 1994, Journal of the National Cancer Institute.

[28]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[29]  F. DeRubertis,et al.  Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. , 1992, Carcinogenesis.

[30]  G. Kelloff,et al.  Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. , 1993, Carcinogenesis.

[31]  F. Hirata,et al.  Aspirin inhibits phospholipase C. , 1986, Biochemical and biophysical research communications.

[32]  R. Everson,et al.  Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study , 1994, Epidemiology.

[33]  S. Shapiro,et al.  A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. , 1991, Journal of the National Cancer Institute.

[34]  T. Hakulinen,et al.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. , 1978, Journal of chronic diseases.

[35]  K. Ewe,et al.  Fecal blood loss in patients with colonic polyps: a comparison of measurements with 51chromium-labeled erythrocytes and with the Haemoccult test. , 1982, Gastroenterology.